Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment

Calcified Tissue International

Volumn 82, Issue 5, 2008, Pages 354-360

  Allen, Matthew R ^a   Reinwald, Susan ^a   Burr, David B ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

Biomechanical property; Bisphosphonate; Cortical bone; Microcrack; Remodeling suppression

Indexed keywords

ALENDRONIC ACID; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE INJURY; BONE MATURATION; BONE STRESS; BONE STRUCTURE; BONE TOUGHNESS; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; DOG; DRUG DOSE COMPARISON; FEMALE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RIB; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; COMPRESSIVE STRENGTH; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HARDNESS; RIBS;

EID: 45849120957     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9131-8     Document Type: Article

References (15)

1. Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879
2. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531
3. Allen MR, Burr DB (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22:1759-1765
4. Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18:512-520
5. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620
6. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2004) Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19:999-1005
7. Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H (2005) Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib (JBMR Anniversay Classic reprint). J Bone Miner Res 20:2066
8. Allen MR, Follet H, Khurana M, Burr DB (2006) Anti-remodeling agents influence osteoblast activity differently in modeling- and remodeling-associated bone formation Calcif Tissue Int 79:255-261
9. Martin RB, Yeh OC, Fyhrie DP (2007) On sampling bones for microcracks. Bone 40:1159-1165
10. Parfitt A, Drezner M, Glorieux F, Kanis J, Malluche H, Meunier P, Ott S, Recker R (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
11. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608
12. Currey J (2004) Incompatible mechanical properties in compact bone. J Theor Biol 231:569-580
13. Allen MR, Burr DB (2008) Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 19:95-99
14. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, Bonvoisin B, Meunier PJ (2004) Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15:231-237
15. Bone HG, Hosking D, Devogelaer J-P, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189-1199